Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Piper Jaffray Upgrades Myriad Genetics


Piper Jaffray upgraded Myriad Genetics (MYGN) to outperform from market perform.

Analyst Edward Tenthoff says looking into 2005, he expects clinical progress and data to be the primary value driver for the drug discovery space.

He offers top discovery picks for 2005: deCode Genetics (outperform), Exelisis (outperform), as well as a Myriad Genetics upgrade. He says Myriad Genetics is scheduled to report Phase II Alzheimer's disease data on Flurizan (R-flurbiprofen) in the second quarter. He also notes the company is on track to file several Investigative New Drug applications in the next few months.

He believes Myriad Genetics continues to deliver strong growth with its Predictive Medicine tests, enabling it to offset its burn rate and conserve cash.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus